UPDATE - UBS upgrades Array BioPharma (Nasdaq: ARRY) from Neutral to Buy. PT $4.25.

UBS analyst says, "We believe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE